JP2023504914A5 - - Google Patents

Info

Publication number
JP2023504914A5
JP2023504914A5 JP2022534664A JP2022534664A JP2023504914A5 JP 2023504914 A5 JP2023504914 A5 JP 2023504914A5 JP 2022534664 A JP2022534664 A JP 2022534664A JP 2022534664 A JP2022534664 A JP 2022534664A JP 2023504914 A5 JP2023504914 A5 JP 2023504914A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
isvd
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022534664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504914A (ja
JP7641968B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/085304 external-priority patent/WO2021116182A1/en
Publication of JP2023504914A publication Critical patent/JP2023504914A/ja
Publication of JP2023504914A5 publication Critical patent/JP2023504914A5/ja
Priority to JP2025025563A priority Critical patent/JP2025081540A/ja
Application granted granted Critical
Publication of JP7641968B2 publication Critical patent/JP7641968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022534664A 2019-12-09 2020-12-09 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド Active JP7641968B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025025563A JP2025081540A (ja) 2019-12-09 2025-02-20 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945391P 2019-12-09 2019-12-09
US62/945,391 2019-12-09
EP20305064 2020-01-27
EP20305064.6 2020-01-27
PCT/EP2020/085304 WO2021116182A1 (en) 2019-12-09 2020-12-09 Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025025563A Division JP2025081540A (ja) 2019-12-09 2025-02-20 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Publications (3)

Publication Number Publication Date
JP2023504914A JP2023504914A (ja) 2023-02-07
JP2023504914A5 true JP2023504914A5 (cg-RX-API-DMAC7.html) 2023-10-17
JP7641968B2 JP7641968B2 (ja) 2025-03-07

Family

ID=73793214

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022534664A Active JP7641968B2 (ja) 2019-12-09 2020-12-09 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
JP2025025563A Pending JP2025081540A (ja) 2019-12-09 2025-02-20 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025025563A Pending JP2025081540A (ja) 2019-12-09 2025-02-20 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Country Status (14)

Country Link
US (5) US20210188965A1 (cg-RX-API-DMAC7.html)
EP (1) EP4072674A1 (cg-RX-API-DMAC7.html)
JP (2) JP7641968B2 (cg-RX-API-DMAC7.html)
KR (1) KR102984686B1 (cg-RX-API-DMAC7.html)
CN (1) CN114980974A (cg-RX-API-DMAC7.html)
AU (1) AU2020400938A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022010223A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163910A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022008813A2 (cg-RX-API-DMAC7.html)
IL (1) IL293548A (cg-RX-API-DMAC7.html)
MX (1) MX2022007035A (cg-RX-API-DMAC7.html)
MY (1) MY208649A (cg-RX-API-DMAC7.html)
TW (2) TWI861302B (cg-RX-API-DMAC7.html)
WO (1) WO2021116182A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
CN114980974A (zh) 2019-12-09 2022-08-30 艾伯霖克斯公司 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
WO2022063984A1 (en) * 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
CA3217029A1 (en) * 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
KR20250025381A (ko) 2022-06-17 2025-02-21 아포지 바이오로직스, 인크. 인터류킨 13에 결합하는 항체 및 사용 방법
WO2024017915A1 (en) * 2022-07-18 2024-01-25 Ablynx N.V. Cx3cr1-binding compounds, uses thereof and related methods
CN118005784A (zh) 2022-11-08 2024-05-10 上海洛启生物医药技术有限公司 抗il-13长效纳米抗体序列及其应用
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
AU2024247861A1 (en) 2023-03-24 2025-11-06 Sanofi Asthma treatment by blocking il-13 and tslp
EP4435005A1 (en) 2023-03-24 2024-09-25 Sanofi Asthma treatment by blocking il-13 and tslp
EP4731663A2 (en) * 2023-06-22 2026-04-29 Paragon Therapeutics, Inc. Antibodies that bind interleukin 13 and tslp or tslpr and methods of use
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
AR134101A1 (es) * 2023-10-12 2025-12-03 Innovent Biologics Suzhou Co Ltd Anticuerpos anti-tslp y usos de los mismos
WO2025209486A1 (en) * 2024-04-02 2025-10-09 Keymed Biosciences (Chengdu) Co., Ltd. Antibodies targeting il-13 and tslp and uses thereof
WO2026041740A1 (en) 2024-08-21 2026-02-26 Sanofi Treatment of high-risk asthma by blocking il-13 and tslp
WO2026055143A2 (en) * 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13-binding polypeptides and uses thereof
WO2026067440A1 (zh) * 2024-09-29 2026-04-02 四川科伦博泰生物医药股份有限公司 Tslp/il-13双特异性抗体及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US20100113339A1 (en) * 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
AR064333A1 (es) * 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
CA2744588A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Ligands that bind il-13
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
HUE057241T2 (hu) 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
US10544222B2 (en) * 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
CA3006398A1 (en) * 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
US11248057B2 (en) * 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
EP4442709A3 (en) 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
KR20260100427A (ko) * 2018-03-28 2026-06-29 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
CN112687354B (zh) * 2019-01-29 2022-07-12 杭州纽安津生物科技有限公司 针对靶向药物PI3K、AKT、mTOR通路的激酶抑制剂的多肽疫苗组合及其设计方法
CN114980974A (zh) 2019-12-09 2022-08-30 艾伯霖克斯公司 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp

Similar Documents

Publication Publication Date Title
JP2023553697A5 (cg-RX-API-DMAC7.html)
JP2020186248A5 (cg-RX-API-DMAC7.html)
CN108473563B (zh) 改进的tnf结合剂
ES2199941T3 (es) Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j.
JP2017529067A (ja) Cd3結合ドメイン
US20210228688A1 (en) Serum Albumin-Binding Fibronectin Type III Domains
AU2017361846A1 (en) T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
JP2023505492A5 (cg-RX-API-DMAC7.html)
JP2019506839A5 (cg-RX-API-DMAC7.html)
CA3165855A1 (en) Mutant rsv f protein and use thereof
JP2017519503A5 (cg-RX-API-DMAC7.html)
CN104292331B (zh) 人源抗人α干扰素抗体及其应用
JP2026004299A5 (cg-RX-API-DMAC7.html)
JP2023544211A5 (cg-RX-API-DMAC7.html)
JP2023545707A5 (cg-RX-API-DMAC7.html)
JP2024504777A (ja) Multabody構築物、組成物および方法
JP2025530888A5 (cg-RX-API-DMAC7.html)
JP2024531346A5 (cg-RX-API-DMAC7.html)
JP2024501767A5 (cg-RX-API-DMAC7.html)
JP2024525213A5 (cg-RX-API-DMAC7.html)
JP2022530742A5 (cg-RX-API-DMAC7.html)
JP2017518770A (ja) 新規ポリペプチド
WO2016112497A1 (zh) 人源抗人α干扰素抗体及其应用
WO2023178306A3 (en) Compositions and methods for treatment of sjögren's syndrome and/or systemic lupus erythematosus
JP2024501770A5 (cg-RX-API-DMAC7.html)